21. The method of claim 19, wherein the antibody or fragment thereof is a humanized antibody.

22. The method of claim 19, wherein the antibody or fragment thereof is a human antibody.

23. The method of claim 19, wherein the antibody or fragment thereof is a F(ab) or Fab' fragment.

24. The method of claim 19, wherein the antibody or fragment thereof is produced by the hybridoma cell line ATCC No. HB 12078.

25. The method of claim 19, wherein the cancer is selected from breast cancer, ovarian cancer, prostate cancer, gastric cancer, and colorectal cancer.

26. The method of claim 19, wherein the overexpression of Her2 is at least 10% higher than a normal basal level.

27. The method of claim 19, wherein the overexpression of Her2 is at least 20% higher than a normal basal level.

28. The method of claim 19, wherein the overexpression of Her2 is at least 30% higher than a normal basal level.

29. The method of claim 19, wherein the antibody or fragment thereof is administered with a chemotherapeutic agent.

30. The method of claim 29, wherein the chemotherapeutic agent is selected from cisplatin and 5-fluorouracil.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

31. The method of claim 19, wherein the antibody or fragment thereof is conjugated to a cytotoxic agent.

32. The method of claim 31, wherein the cytotoxic agent is selected from an A chain toxin, a ribosome inactivating protein, and a ribonuclease.

33. The method of claim 19, wherein the antibody or fragment thereof is administered parenterally, subcutaneously, intravenously, or intramuscularly.

34. The method of claim 19, wherein the antibody or fragment thereof is a monoclonal antibody that binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078.

35. The method of claim 19, wherein the antibody or fragment thereof is a humanized antibody that binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078.

36. The method of claim 19, wherein the antibody or fragment thereof is a human antibody that binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078.

37. The method of claim 19, wherein the antibody or fragment thereof is a F(ab) or Fab' fragment that binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078.

38. The method of claim 19, wherein the antibody or fragment thereof binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

cell line ATCC No. HB 12078, and wherein the cancer is selected from breast cancer, ovarian cancer, prostate cancer, gastric cancer, and colorectal cancer.

39. The method of claim 19, wherein the antibody or fragment thereof binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078, and wherein the overexpression of Her2 is at least 10% higher than a normal basal level.

40. The method of claim 39, wherein the overexpression of Her2 is at least 20% higher than a normal basal level.

41. The method of claim 40, wherein the overexpression of Her2 is at least 30% higher than a normal basal level.

42. The method of claim 19, wherein the antibody or fragment thereof binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078, and wherein the antibody or fragment thereof is administered with a chemotherapeutic agent.

43. The method of claim 42, wherein the chemotherapeutic agent is selected from cisplatin and 5-fluorouracil.

44. The method of claim 19, wherein the antibody or fragment thereof binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078, and wherein the antibody or fragment thereof is conjugated to a cytotoxic agent.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

45. The method of claim 44, wherein the cytotoxic agent is selected from an A chain toxin, a ribosome inactivating protein, and a ribonuclease.

46. The method of claim 19, wherein the antibody or fragment thereof binds an epitope on Her2 which is recognized by a monoclonal antibody produced by hybridoma cell line ATCC No. HB 12078, and wherein the antibody or fragment thereof is administered parenterally, subcutaneously, intravenously, or intramuscularly.

47. A method for inducing apoptosis in Her2 expressing cells comprising administering an amount of an antibody or fragment thereof, wherein said amount is sufficient to induce apoptosis in said Her2 expressing cells.

48. The method of claim 47, wherein the antibody or fragment thereof is a monoclonal antibody.

49. The method of claim 47, wherein the antibody or fragment thereof is a humanized antibody.

50. The method of claim 47, wherein the antibody or fragment thereof is a human antibody.

51. The method of claim 47, wherein the antibody or fragment thereof is a F(ab) or Fab' fragment.

52. The method of claim 47, wherein the antibody or fragment thereof is produced by the hybridoma cell line ATCC No. HB 12078.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com